2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P3692
    CART (55-76), rat 1815618-15-5 98%
    CART (55-76), rat is a neuropeptide (55-76 residues of the CART peptide) and constitutes the N-terminal fragments of CART (55-102). CART (55-76), rat is a rat satiety factor with potent appetite-suppressing activity and is closely associated with leptin and neuropeptide Y. CART (55-76), rat can induce anxiety and stress-related behavior.
    CART (55-76), rat
  • HY-P3712
    Cardioexcitatory peptide 1 127122-98-9 98%
    Cardioexcitatory peptide 1 is a cardioexcitatory neuropeptide, can be isolated from Achatina atria. Cardioexcitatory peptide 1 has potent cardio-excitatory action on the hearts and also modifies the motility of muscular tissues and neural activities.
    Cardioexcitatory peptide 1
  • HY-P3721
    Miraculin (1-20) 198694-37-0 98%
    Miraculin (1-20) is a peptide, comprised of 20 amino acids.
    Miraculin (1-20)
  • HY-P3741
    [Ala9,10, Lys11,12] Glycogen Synthase (1-12) 105802-84-4 98%
    [Ala9,10, Lys11,12] Glycogen Synthase (1-12) is a selective substrate for phosphorylation by protein kinase C (PKC). [Ala9,10, Lys11,12] Glycogen Synthase (1-12) can be used to determine the activity of protein kinase C.
    [Ala9,10, Lys11,12] Glycogen Synthase (1-12)
  • HY-P3775
    a-Bag Cell Peptide (1-7) 87549-54-0 98%
    a-Bag Cell Peptide (1-7) is a NH2-terminal fragment α-bag cell peptide. α-bag cell peptide can inhibit the left upper quadrant (LUQ) neurons and the depolarization of the bag cells. α-Bag Cell Peptide Fragment
    a-Bag Cell Peptide (1-7)
  • HY-P3776
    a-Bag Cell Peptide (1-8) 87549-53-9 98%
    a-Bag Cell Peptide (1-8) is a NH2-terminal fragment α-bag cell peptide. α-bag cell peptide can inhibit the left upper quadrant (LUQ) neurons and the depolarization of the bag cells.
    a-Bag Cell Peptide (1-8)
  • HY-P3777
    β-Bag cell peptide 109024-47-7 98%
    β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents.
    β-Bag cell peptide
  • HY-P3778
    γ-Bag cell peptide 109024-48-8 98%
    γ-bag cell peptide is a peptide. γ-bag cell peptide is located near the N-terminus of the egg laying prohormone, the vesicle is released upon insulin stimulation. γ-bag cell peptide can be used for the research of the central and peripheral nervous systems.
    γ-Bag cell peptide
  • HY-P3779
    Amyloid 17-42 155178-13-5 98%
    Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of the amyloid precursor protein (APP). Amyloid 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway.
    Amyloid 17-42
  • HY-P3780
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) 1802078-25-6 98%
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment.
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)
  • HY-P3781
    (Met(O)35)-Amyloid β-Protein (1-42) 98%
    (Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD).
    (Met(O)35)-Amyloid β-Protein (1-42)
  • HY-P3785
    PKI(5-22)amide 100853-58-5 98%
    PKI(5-22)amide is the active inhibitory fragment of the inhibitor of the cyclic AMP-dependent protein kinase (PKA). PKI(5-22)amide inhibits PKA activation, but fails to attenuate homologous desensitization of CRF1 receptors.
    PKI(5-22)amide
  • HY-P3793
    Amyloid β-Protein (33-42) (TFA) 98%
    Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity.
    Amyloid β-Protein (33-42) (TFA)
  • HY-P3799
    [Glp6] Substance P (6-11) 61123-13-5 98%
    [Glp6] Substance P (6-11) is an analogue of substance P (6-11). Substance P (6-11) stimulates [3H]-inositol monophosphate ([3H]-IP1) formation in rat urinary bladder by acting on the 'septide-sensitive' tachykinin receptors.
    [Glp6] Substance P (6-11)
  • HY-P3800
    [Glp5] Substance P (5-11) 56104-22-4 98%
    [Glp5] Substance P (5-11) is an octapeptide. [Glp5] Substance P (5-11) is one of the main substance P fragments in rat central nervous system (CNS). [Glp5] Substance P (5-11) locally modulates dopamine release in rat striatum.
    [Glp5] Substance P (5-11)
  • HY-P3802
    [D-Trp2,7,9] Substance P 100930-11-8 98%
    [D-Trp2,7,9] Substance P is a tachykinin (Neurokinin Receptor) antagonist with Ki values of 1 μM, 1.3 μM, and ~9 μM for NK-1, NK-2,and NK-3 receptor, respectively.
    [D-Trp2,7,9] Substance P
  • HY-P3803
    [D-Pro4,D-Trp7,9] Substance P (4-11) 81039-85-2 98%
    [D-Pro4,D-Trp7,9] Substance P (4-11) is a potent antagonist of Substance P (HY-P0201). [D-Pro4,D-Trp7,9] Substance P (4-11) decreases plasma aldosterone (ALDO) concentration.
    [D-Pro4,D-Trp7,9] Substance P (4-11)
  • HY-P3805
    [D-Pro4,D-Trp7,9,Nle11] Substance P (4-11) 89430-34-2 98%
    [D-Pro4,D-Trp7,9,Nle11] Substance P (4-11) is a potent neurokinin NK1 antagonist. [D-Pro4,D-Trp7,9,Nle11] Substance P (4-11) inhibits the effects of gold-protein-substance P (GPSP) and substance P (SP).
    [D-Pro4,D-Trp7,9,Nle11] Substance P (4-11)
  • HY-P3809
    [D-Pro2,D-Phe7,D-Trp9] Substance P 77275-70-8 98%
    [D-Pro2,D-Phe7,D-Trp9] Substance P is a Substance P (HY-P0201) analogue. [D-Pro2,D-Phe7,D-Trp9] Substance P is an inhibitor of Substance P. [D-Pro2,D-Phe7,D-Trp9] Substance P contracts guinea-pig ileum (GPI) indirectly.
    [D-Pro2,D-Phe7,D-Trp9] Substance P
  • HY-P3811
    Autocamtide-3 142828-10-2 98%
    Autocamtide-3, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca2+/calmodulin-dependent kinase II) (CaMK) substrate.
    Autocamtide-3
Cat. No. Product Name / Synonyms Application Reactivity